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Tiago Guimarães1,2,3, Ana Cristina Santos1,4, Raquel Lucas1,4
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We aimed to describe bone formation and resorption markers in generally healthy prepuber-
tal children using total alkaline phosphatase (tALP), osteocalcin (OC) and β-isomerized C-
terminal telopeptides of type I collagen (β-CTx) serum concentrations and to estimate mark-
ers’ correlations with anthropometric growth (height, weight, body mass index and trajecto-
ries of weight gain) as well as bone mineral content (BMC) and areal density (aBMD).
Methods
We assessed 395 7-year-old children from the Generation XXI cohort with tALP, OC and β-
CTx concentrations determined from a fasting venous blood sample and BMC/aBMD mea-
sured by dual-energy X-ray absorptiometry. Gender-specific reference intervals for tALP,
OC and β-CTx in 7-year-old children were established by calculating the 2.5th and 97.5th
percentiles. Pearson and partial correlation coefficients (controlling for sex, age, body size
and season) between bone markers and growth measures were computed.
Results
tALP increased with height (rpartial controlled for sex = 0.26, 95%CI: 0.17, 0.35), was higher
in overweight than in healthy weight children, and in children who gained weight above aver-
age during infancy. No correlations were found between OC or β-CTx and growth. In girls,
OC was slightly correlated with subtotal BMC (rpartial = 0.22, 95%CI: 0.08, 0.35), subtotal
aBMD (rpartial = 0.20, 95%CI: 0.06, 0.33) and lumbar spine aBMD (rpartial = 0.23, 95%CI:
0.09, 0.36). tALP and β-CTx were not correlated with any of the DXA-derived bone
measures.







Citation: Monjardino T, Silva P, Amaro J, Carvalho
O, Guimarães JT, Santos AC, et al. (2019) Bone
formation and resorption markers at 7 years of
age: Relations with growth and bone
mineralization. PLoS ONE 14(8): e0219423. https://
doi.org/10.1371/journal.pone.0219423
Editor: Dominique Heymann, Universite de Nantes,
FRANCE
Received: March 6, 2019
Accepted: June 24, 2019
Published: August 22, 2019
Copyright: © 2019 Monjardino et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was funded by the European
Regional Development Fund (ERDF), through the
Operational Programme Competitiveness and
Internationalization, and national funding from the
Foundation for Science and Technology (FCT) -
Portuguese Ministry of Science, Technology and
Higher Education - under the projects “STEPACHE
- Raı́zes pediátricas da resposta ampliada à dor:
Conclusion
This study contributed to the description of bone turnover at 7 years of age and suggested
that bone metabolism markers measured in a single point in time have limited ability to
describe anthropometric growth and overall bone status in generally healthy prepubertal
children.
Introduction
Serum bone metabolism markers are bone-derived molecules released into circulation as a
result of osteoblast or osteoclast activity that can be used to describe bone formation or resorp-
tion, respectively [1]. In adults, bone turnover markers reflect the lifelong process of bone
remodeling, and have been proposed as independent predictors of bone density and fracture
risk [2, 3]. They have also been used to assist the selection of drug treatments for osteoporosis
and to monitor the effectiveness of antiresorptive therapies [4, 5].
In children, the meaning of bone metabolism markers is more complex, as they reflect not
only background homeostatic remodeling but also two intensive processes that are hallmarks
of growth, i.e. bone modeling and linear growth of the skeleton [6]. As such, bone metabolism
markers are mainly used in clinical pediatrics for the monitoring of certain chronic conditions
that interfere with bone homeostasis and thus with normal skeletal growth and development,
including osteogenesis imperfecta, juvenile idiopathic arthritis, and chronic kidney disease [7].
Much less is known about the usefulness of bone formation and resorption markers to describe
bone development or growth trajectories in the healthy skeleton. From a practical perspective,
for instance in large-scale epidemiological studies aiming to assess bone mineralization in pop-
ulation-based samples of children, measurement of serum levels bone formation and resorp-
tion could be an interesting alternative to bone mass estimation using dual-energy X-ray
absorptiometry (DXA), since the former may demand lower resources, while avoiding radia-
tion exposure [7]. Bone metabolism markers have also the potential to be more sensitive to
short-term changes to bone turnover rates [6]. Nevertheless, it is not clear at present whether
serum levels of bone metabolism markers add useful information to describe childhood
growth, given their high preanalytical variability [8].
Most previous studies exploring the relation between bone metabolism markers and growth
have used cross-sectional designs and have described associations in relatively small samples
of children, with wide age ranges [9–17]. Additionally, most existing evidence was obtained
from convenience or clinical-based samples where distributions of bone markers are not nec-
essarily representative of those in the source population [18, 19]. Therefore, by using data from
a population-based sample of prepubertal children of the same age, we aimed to describe bone
formation and resorption markers using total alkaline phosphatase (tALP), osteocalcin (OC)
and β-isomerized C-terminal telopeptides of type I collagen (β-CTx), and to assess whether
those bone metabolism markers are associated with DXA-derived bone properties and anthro-
pometric growth up to seven years of age.
Materials and methods
We used data from a sub-sample of 395 children, recruited and followed up as part of Genera-
tion XXI, a prospective birth cohort assembled in 2005/06 at public maternity units in Porto,
Portugal [20, 21].
Bone metabolism markers in prepubertal children
PLOS ONE | https://doi.org/10.1371/journal.pone.0219423 August 22, 2019 2 / 16
das influências contextuais à estratificação do risco
(POCI-01-0145-FEDER-029087; PTDC/SAU-EPI/
29087/2017); “BioAdversity: Como a adversidade
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Generation XXI cohort assembly and follow-up
All live infants with more than 23 weeks of gestation, born in one of the five public maternity
units in the Porto Metropolitan Area, between April 2005 and August 2006, were eligible to
participate. Of the invited mothers, 91.4% accepted to participate and their 8647 infants were
enrolled in the cohort study. Seven years after birth (April 2012 to April 2014), all Generation
XXI participants were invited to a follow-up evaluation and, of the initial cohort, 5849 (67.6%)
were interviewed face to face. In each evaluation, we obtained written informed consent from
parents or legal guardians and additional oral assent from children at 7 years of age. The study
protocol complies with the 1964 Declaration of Helsinki and was approved by the Ethics Com-
mittee of University of Porto Medical School/Hospital de São João, Porto, Portugal, and regis-
tered with the Portuguese Data Protection Authority.
Study sample
From the 5849 children evaluated at 7 years of age we selected a subsample of 400 participants
to measure bone metabolism markers and bioactive molecules: serum 25-hydroxyvitamin D
(25(OH)D), intact parathyroid hormone (PTHi), calcium (Ca) and inorganic phosphorus (Pi).
Sample size was calculated based on expected correlations between bone parameters, in order
to allow estimating a 0.15 linear correlation coefficient with an 85% power at a 0.05 signifi-
cance level. These participants were selected based on the following characteristics: 1) to be a
singleton full-term baby (more than 36 weeks of gestation); 2) to have a valid whole body DXA
scan at 7 years, 3) to have a fasting blood sample collected in the morning with enough volume
to perform the intended laboratory analyses. From all participants with the aforementioned
characteristics, we randomly selected 200 boys and 200 girls. After samples were sent for analy-
sis, we excluded a further five children as their samples were hemolytic, icteric or lipemic, leav-
ing 395 children for the current analysis (49.9% girls).
Children included in the present study were not different from the remaining cohort
regarding sex distribution (49.9% girls vs. 49.0%, p = 0.719), height at 7 years of age (123.3 vs.
123.7 cm, p = 0.146) and weight at 7 years of age (25.9 vs. 26.2 kg, p = 0.176). However, partici-
pants included had lower bone mineral content (BMC) (585.0 g in included vs. 604.8 g in
excluded participants, p< 0.001) than those excluded.
Blood sampling and serum determinations
At the 7 years of age follow-up evaluation, we collected blood samples drawn from an antecu-
bital vein, in the morning after overnight fasting. All children were offered local dermal analge-
sia with lidocaine/prilocaine (EMLA). Blood samples were collected in Vacumed vacuum
tubes with gel separator plus clot activator (FL medical, Italy), allowed to clot for 20 minutes at
room temperature and centrifuged for 15min at 1500 ×g. Serum was aliquoted and kept frozen
at -80˚C in the biobank at the University of Porto Medical School until the day of analysis. All
analytical measurements presented in this paper were conducted at the clinical pathology labo-
ratory of the Centro Hospitalar São João, EPE in Porto, Portugal, in June 2014, after being
thawed according to standard operating procedures.
Total alkaline phosphatase (tALP) was quantified by a spectrophotometric method based
on the conversion of p-nitro-phenylphosphate (pNPP) to p-nitrophenol (pNP) measured at
410/480 nm on an Olympus AU5400 analyzer (Beckman Coulter Inc., USA) (the detection
range of the kit, defined by the detection limit and the calibration curve maximum concentra-
tion, is 5–1500 units/l, U/l).
Osteocalcin (OC), β-isomerized C-terminal telopeptides of type I collagen (β-crosslaps, β-
CTx), and parathyroid hormone measurements were performed by electro-chemiluminescence
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immunoassays (ECLIA) in a Cobas e411 analyzer (Roche Diagnostics GmbH, Mannheim, Ger-
many) [22]. The Elecsys N-MID Osteocalcin assay (Roche Cobas, Roche Diagnostics, Mann-
heim, Germany) detects both the stable N-terminal mid-fragment of OC (amino acids 1–43)
and intact Osteocalcin (aminoacids 1–49) (detection range: 0.500–300 μg/l). The Elecsys β-
crosslaps assay/serum quantifies all degradation fragments of the C-terminal telopeptide region
of type I collagen α1 chain that contain the β-isomerized octapeptide EKAHD-β-GGR twice (β-
CTx) [23]. This test uses two mouse monoclonal antibodies directed against different regions of
the EKAHD-β-GGR octapeptide (detection range: 10–6000 ng/l). Parathyroid hormone was
measured as PTHi, a single polypeptide chain containing 84 amino acids. Two different mono-
clonal antibodies, directed against the aminoacid regions 26–32 (N-terminal) and 37–42 (C-ter-
minal) were used (detection range: 0.127–530 pmol/l).
Serum 25(OH)D concentration was determined using LIAISON 25-OH Vitamin D Total
assay (DiaSorin, Saluggia, Italy), a direct competitive chemiluminescence immunoassay which
recognizes 25 (OH) vitamin D2 and 25 (OH) vitamin D3 and is fully automated using a Liason
platform (detection range: 4.0–150 ng/ml) [24].
Ca and Pi were determined using the Olympus AU5400 analyzer. Ca was detected by a col-
orimetric assay where Calcium ions (Ca2+) react with Arsenazo III and produce an intense
purple color complex (detection range: 1–5 mmol/l) (Beckman Coulter AU System Calcium
Arsenazo, Beckman Coulter). Pi was determined by a colorimetric assay were the absorbance
at 340/380 nm is directly proportional to the Pi level in the sample (Beckman Coulter AU Sys-
tem Inorganic Phosphorus Reagent, Beckman Coulter) (detection range: 0.32–6.40 mmol/l).
All analytical measurements were performed according the manufacturer’s instructions
regarding preventive maintenance, function checks, calibration, and quality control of both
tests and equipment. All samples tested underwent automated interference analysis for hemo-
lysis, hyperbilirubinemia and lipemia.
Physical examination
Anthropometry was obtained while the child stood barefoot in light indoor clothing. Weight
was measured to the nearest 0.1kg using a digital scale (TANITA, Arlington Heights, IL, USA)
and height was measured to the nearest 0.1cm using a wall stadiometer (SECA, Hamburg, Ger-
many). Body mass index (BMI, kg/m2) was calculated as the ratio of weight to height squared
and BMI-for-age values were classified according to the World Health Organization reference
data for BMI z-score into the following categories: normal weight (�+1 SD) and overweight
(>+1 SD, including children with overweight and obesity) [25]. In our sample no children
were underweight according to the cut-off value <-2 SD. The definition of weight trajectories
in the cohort was based on an extensive body of anthropometric measurements abstracted
from the children’s health books, recorded in routine care, from birth until the age of 6 years.
Four different weight trajectories for both sexes combined were identified through normal
mixture modeling for model-based clustering and labelled “normal weight gain”, “weight gain
during infancy”, “weight gain during childhood” and “persistent weight gain”, as previously
described [26] (Figure A in S1 File).
Whole body DXA scans were performed in a Hologic Discovery QDR 4500W device (Holo-
gic Inc., Bedford, Massachusetts), according to standard manufacturer protocols in light cloth-
ing and without metal accessories. Total body less head (subtotal) and lumbar spine (LS) BMC
was obtained and areal bone mineral density (aBMD) was expressed as BMC (in g) per pro-
jected bone area (in cm2) [27]. We performed daily standard quality assurance tests using the
spine phantom. Scans were evaluated immediately after the scanning procedure and later vali-
dated by a second well-trained radiology technician.
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Data analysis
For the description of reference intervals, according to the C28-A3 International Federation of
Clinical Chemistry and Clinical Laboratory and Standards Institute guidelines (C28-A3 CLSI/
IFCC guidelines), data were examined for outlier observations using frequency histograms and
Dixon outlier range statistic as follows. Estimation of D/R ratio, where D is the absolute differ-
ence between the most extreme observation (large or small) and the next largest (or smallest)
observation and R is the range of all observations (maximum-minimum) was estimated. If the
ratio D/R exceeds 1/3, then the extreme observation is deleted, otherwise all datum is kept [28].
Using this procedure, no extreme values were detected as outliers for any of the bone markers
distributions. Concentrations of bone metabolism markers are presented as medians, and the
interval limits were determined by calculating the rank numbers for the 2.5th and 97.5th percen-
tiles of the distribution [28]. The season during which blood samples were collected was com-
bined into two categories: summer (April-September) and winter months (October-March).
Two-sample t test, Mann–Whitney test and chi-square test were used to compare boys and
girls with regard to bone markers concentrations, age, anthropometrics (height, weight, BMI
and trajectories of weight gain), 25(OH)D, PTHi, Ca and Pi.
Correlations were estimated using parametric statistics (Pearson correlation coefficients) to
assess crude relationships among bone metabolism markers and between bone markers and
age, height, weight and DXA-derived BMC and aBMD. To account for the effects of age, sex,
body size (height and weight) and season on the relationships studied we computed Pearson
partial correlations (rpartial). Correlations below 0.20 were interpreted as very weak, between 0.2
and 0.4 as weak and between 0.4 and 0.6 as moderate. Concentrations of bone markers were
compared between BMI groups using Mann–Whitney test and between weight gain trajectories
using ANOVA. Mean values of bone markers concentrations, adjusted for sex, age and season
were estimated through ANCOVA and comparisons between BMI groups were performed
using nlcom command in Stata. Mean values of bone markers concentrations according to
weight gain trajectories were additionally adjusted for current body size (height and weight at 7
years of age) and comparisons between trajectories were performed using Wald test (testparm
command in Stata). Post-hoc pairwise comparison of adjusted means between trajectories were
performed with the Tukey-Kramer correction for multiple comparison.
Sensitivity analyses
To assess the impact of vitamin D deficiency on the relationships between bone markers and
anthropometrics and BMC/aBMD, we recalculated correlations after excluding children with
serum 25(OH)D below 20 ng/ml [29] (n = 153), and compared these estimates with those
obtained for the whole sample. Additional sensitivity analyses to assess the impact of hypo- or
hypercalcemia and hypo- or hyperphosphatemia were carried out by excluding children with
serum Ca or Pi concentrations outside reference intervals established by the instrument manu-
facturer (Ca below 2.2 mmol/l or above 2.7 mmol/l, n = 58; Pi below 1.292 mmol/l or above
2.261 mmol/l, n = 3) [30].
All statistical analyses were conducted by using Stata version 11.2 for Windows (Stata Corp.
LP, College Station, Texas, USA).
Results
Sample characteristics
In our sample of 7-year-old children, reference intervals expressed as 2.5th to 97.5th percentile
were 159 to 439 U/l for serum tALP and 470 to 1690 ng/l for β-CTx. Since mean OC
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concentration was higher in girls than in boys (87.9 versus 82.1 μg/l, respectively, p = 0.003),
reference intervals are presented separately by sex: 52.5 to 137.7 μg/l in girls and 50.0 to
129.9 μg/l in boys. Seasonal variation of bone metabolism markers was observed, with
increased levels of tALP (p<0.001) and β-CTx (p = 0.003) in children sampled in summer
(n = 314) than in those sampled in winter months (n = 81) (Table 1).
There were no differences between girls and boys in age, weight and BMI distributions.
Girls were slightly shorter than boys (122.7 versus 123.8 cm, p = 0.022) had lower serum Pi
concentration (1.63 versus 1.66 mmol/l, p = 0.025), and were more likely to have a trajectory
of weight gain during childhood. Serum vitamin D level was higher in samples of participants
evaluated in summer than in winter months (p<0.001). Vitamin D insufficiency was present
in 45.6% children while vitamin D deficiency was present in 38.7% children [29] (Table 1).
Relationship between bone formation and resorption
In both sexes, positive moderate correlations between OC and β-CTx were found, even after
controlling for age, body size and season effects (girls: rpartial = 0.40, 95%CI: 0.28, 0.51 and
boys: rpartial = 0.46, 95%CI: 0.34, 0.56). No relevant correlations were observed between tALP
and OC (girls: rpartial = 0.02, 95%CI: -0.12 0.16 and boys: rpartial = 0.07, 95%CI: -0.07, 0.21) or
between tALP and β-CTx (girls: rpartial = 0.13, 95%CI: -0.01, 0.27 and boys: rpartial = 0.00, 95%
CI: -0.14, 0.14) (Table 2).
Bone metabolism markers and age and anthropometrics
Correlations between age and tALP and β-CTx were very weak and attenuated after account-
ing for sex and season effects (rpartial = 0.14, 95%CI: 0.04, 0.23 and rpartial = 0.08, 95%CI: -0.02,
0.17, respectively) (Fig 1A and Fig 1C).
As regards anthropometrics, tALP was slightly correlated with height (r = 0.30, 95%CI:
0.20, 0.38) (Fig 1D) and weight (r = 0.26, 95%CI: 0.16, 0.35) (Fig 1G) while correlations
between height or weight and OC or β-CTx were irrelevant (Fig 1E, Fig 1F, Fig 1H and Fig 1I).
After accounting for the effect of sex, age and season, the positive relationship between height
and tALP was attenuated (rpartial = 0.26, 95%CI: 0.17, 0.35) (Fig 1D). Comparing BMI groups,
we observed that overweight children had higher tALP concentration than normal weight chil-
dren [mean (95% CI) adjusted for sex, age and season: 287 (275, 300) versus 263 (254, 272) U/
l, p = 0.002] (Fig 1J). Also for tALP, we observed that, in comparison to children in a “normal
weight gain” trajectory [mean (95% CI) adjusted for sex, age and season: 268 (259, 278) U/l)],
those in the trajectories of “weight gain during infancy” presented slightly higher serum con-
centrations [308 (278, 339) U/l, p = 0.018] (Fig 1M). For OC and β-CTx, we observed no dif-
ferences in serum concentrations by BMI groups or by trajectories of weight gain (Fig 1K, Fig
1L, Fig 1N and Fig 1O).
Bone metabolism markers and DXA-derived bone measures
Overall, Table 3 shows that correlations between bone metabolism markers and DXA-derived
BMC and aBMD were positive but modest in magnitude. Crude correlations with BMC and
aBMD were slightly stronger for tALP than for OC or β-CTx. Serum OC was slightly stronger
correlated with BMC/aBMD in girls than in boys. However, after computing partial correla-
tions accounting for age, body size and season effects, tALP was no longer correlated with
bone mass, neither in girls nor in boys. In girls only, weak positive correlations between OC
and subtotal BMC (rpartial = 0.22, 95%CI: 0.08, 0.35), subtotal aBMD (rpartial = 0.20, 95%CI:
0.06, 0.33) and lumbar spine aBMD (rpartial = 0.23, 95%CI: 0.09, 0.36) were observed. β-CTx
was not correlated with any of the DXA-derived bone measures.
Bone metabolism markers in prepubertal children
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Table 1. Anthropometrics and serum concentrations of vitamin D, parathyroid hormone, calcium, phosphorus and bone metabolism markers, in girls and boys
(n = 395).
TOTAL Girls (n = 197) Boys (n = 198) Comparison between genders
Mean ± SD or Median (P25, P75) or n (%) p-value a
Age (months) 84.1 (83.6, 84.5) 83.9 (83.7, 84.5) 84.1 (83.6, 84.6) 0.674
Height (cm) 123.3 ± 5.1 122.7 ± 4.9 123.8 ± 5.2 0.022
Weight (kg) 25.2 (22.6, 28.1) 24.9 (22.6, 28.1) 25.2 (22.7, 28.2) 0.774
BMI categories (%) b
Normal weight 262 (66.3) 127 (64.5) 135 (68.2) 0.719
Overweight 81 (20.5) 42 (21.3) 39 (19.7)
Obese 52 (13.2) 28 (14.2) 24 (12.1)
Growth trajectories (%)
Normal weight gain 243 (67.5) 110 (61.1) 133 (73.9) 0.004
Weight gain during infancy 23 (6.4) 9 (5.0) 14 (7.8)
Weight gain during childhood 54 (15.0) 38 (21.1) 16 (8.9)
Persistent weight gain 40 (11.1) 23 (12.8) 17 (9.4)
Missing data for growth trajectory assignment 35 17 18
25(OH)D (ng/ml)
Total sample 21.8 (17.7, 26.3) 22.0 (17.7, 26.6) 21.7 (17.8, 26.0) 0.756
Collected in summer c 23.0 (19.0, 28.0) 23.3 (19.1, 28.2) 22.6 (18.5, 27.8)
Collected in winter d 17.2 (14.1, 21.1) 16.2 (12.9, 20.9) 18.0 (14.8, 21.8)
Vitamin D insufficiency (%) e 180 (45.6) 83 (42.1) 97 (49.0)
Vitamin D deficiency (%) e 153 (38.7) 81 (41.1) 72 (36.7) 0.583
PTHi (pmol/l) 3.24 (2.63, 3.83) 3.28 (2.65, 3.88) 3.20 (2.60, 3.74) 0.608
Ca (mmol/l) 2.5 (2.4, 2.6) 2.5 (2.4, 2.6) 2.5 (2.4, 2.6) 0.308
Pi (mmol/l) 1.64 ± 0.16 1.63 ± 0.16 1.66 ± 0.16 0.025
P50th (P2.5th—P97.5th)
tALP (U/l) f
Total sample 260 (159, 439) 258 (153, 439) 262 (167, 445) 0.820
Collected in summer g 269 (175, 445) 272 (167, 459) 265 (175, 445)
Collected in winter d 228 (139, 396) 220 (134, 396) 239 (139, 584)
OC (μg/l)
Total sample 85.2 (50.3, 134.8) 87.9 (52.5, 137.7) 82.1 (50.0, 129.9) 0.003
Collected in summer c 85.6 (51.6, 136.5) 88.3 (52.5, 140.6) 82.2 (51.1, 130.2)
Collected in winter d 83.6 (50.0, 124.3) 85.2 (59.6, 127.9) 81.6 (48.6, 114.5)
β-CTx (ng/l)
Total sample 1030 (470, 1690) 1040 (450, 1690) 1005 (510, 1690) 0.258
Collected in summer c 1040 (500, 1690) 1075 (450, 1700) 1025 (530, 1680)
Collected in winter d 940 (470, 1380) 930 (500, 1320) 940 (440, 1700)
a Two-sample t-test, Mann–Whitney or chi-square tests as appropriate
b According to World Health Organization reference data for BMI z-score: normal weight (�1 SD), overweight (>1 SD and�2 SD) and obesity (>2 SD) (de Onis, et al.,
Bull World Health Organ, 2007)
c n = 314 (154 Girls + 160 Boys)
d n = 81 (43 Girls + 38 Boys)
e According to the Endocrine Society (United States), vitamin D insufficiency is defined as serum 25(OH)D of 21–29 ng/ml and vitamin D deficiency as serum 25(OH)
D below 20 ng/ml (Holick, et al., J Clin Endocrinol Metab, 2011)
f n = 394 (197 Girls + 197 Boys)
g n = 313 (154 Girls + 159 Boys)
Abbreviations: BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D; PTHi, intact parathyroid hormone; Ca, calcium, Pi, inorganic phosphorus; tALP, total alkaline
phosphatase; OC, osteocalcin; β-CTx, β-crosslaps
https://doi.org/10.1371/journal.pone.0219423.t001
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Sensitivity analyses
After excluding children with vitamin D deficiency (n = 153), with hypo- and hypercalcemia
(n = 58) or hypo- and hyperphosphatemia (n = 3), one group at a time, correlation coefficients
between bone metabolism markers and anthropometrics and DXA-derived bone measures
remained similar to those obtained for the whole sample of children before exclusion of these
subjects.
Discussion
In this study, we described reference intervals for tALP, OC and β-CTx in a population-based
sample of 7-year-old children. We found a moderate correlation between serum concentra-
tions of bone-specific metabolism markers OC and β-CTx, likely representing the dynamic
nature of bone turnover. The non-specific bone marker tALP was slightly more correlated
than OC or β-CTx with bone mass and anthropometric variables, probably reflecting the over-
all trajectory of anthropometric growth up to the time of measurement.
There has been growing interest in the quantification of bone metabolism markers in the
clinical setting as they may provide a dynamic, short-term measure of skeletal status, which is
not captured by bone physical properties alone [2]. So far, no single individual parameter has
fulfilled all the criteria for an ideal marker of bone formation or resorption [6]. The clinical util-
ity of bone markers is challenged by high intraindividual variation, lack of specificity for bone
tissue, release during different anabolic and catabolic processes and influence of non-skeletal
processes on circulating levels [31]. Also, no single marker is sufficiently precise to be used for
prognostic purposes, as concentration changes of candidate molecules are neither site- nor dis-
ease-specific [6]. An additional challenge is posed in the interpretation of bone metabolism
markers as a prognostic tool, in populations of children and adolescents, because it is impossible
to distinguish treatment-induced changes from the physiological age-related decline in these
bone markers [31]. Furthermore, some bone metabolism markers, such as OC, may reflect, at
the same time, both bone formation and resorption processes [31]. Because there is no specific
bone marker to assess bone modeling, remodeling or epiphyseal growth, concentrations of
markers in children represent the combined effects of these different biological processes [6].
This means that equal serum levels of bone metabolism markers can be found both in children
with high bone remodeling and low rate of growth as well as in normally growing children [32].
In addition to limitations in inferring the biological significance of bone metabolism mark-
ers, the definition of pediatric reference intervals is limited by their substantial pre-analytical
Table 2. Pearson correlation and partial correlation coefficients among bone metabolism markers, in girls and boys (n = 395).
Girls (n = 197)
tALP OC β-CTx
Coefficient 95%CI Coefficient 95%CI Coefficient 95%CI
Boys (n = 198) tALP r = 0.06 -0.08, 0.20 r = 0.18 0.04, 0.31
rpartial = 0.02 -0.12, 0.16 rpartial = 0.13 -0.01, 0.27
OC r = 0.11 -0.03, 0.25 r = 0.40 0.28, 0.51
rpartial = 0.07 -0.07, 0.21 rpartial = 0.40 0.28, 0.51
β-CTx r = 0.06 -0.08, 0.20 r = 0.47 0.36, 0.58
rpartial = 0.00 -0.14, 0.14 rpartial = 0.46 0.34, 0.56
Abbreviations: tALP, total alkaline phosphatase; OC, osteocalcin; β-CTx, β-crosslaps; r, Pearson correlation coefficient; rpartial, Pearson partial correlation coefficient
(age, body size and season controlled); 95%CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0219423.t002
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variability and by heterogeneity in analytical methods [8]. Pre-analytical sources of variability
include uncontrollable factors (such as sex, age, pubertal development, growth velocity, ethnic-
ity, physical activity, nutritional status, or pathological conditions (e.g. diabetes, liver diseases,
growth hormone deficiency, vitamin D deficiency, or recent fracture) and drugs), and control-
lable factors such as circadian rhythm, seasonal variation or fasting status [8]. The main
sources of undesired pre analytical variability of tALP are related to age, pubertal status and
sex, as well as lack of bone specificity [32]. Regarding OC, pre-analytical variability is mostly
related to age and circadian rhythm [8]. β-CTx also exhibits significant circadian rhythm and
is influenced by food intake, as well as age [8]. Analytical variability further contributes to vari-
ation of reference intervals, due to lack of standardization and harmonization of quantification
methods and to inter-laboratory variation, even when the same method is used [33]. Attempts
to establish reference intervals have also been limited by the small sample sizes of most previ-
ous investigations, which have also been frequently conducted in hospital settings [33]. Indeed,
reference values obtained from facility-based samples may not be applicable to the general
pediatric population as intervals in the former are generally wider [34].
To account for those limitations, our approach in the present study was to use data from a
comparatively large population-based sample of children of the same age, whose samples were
Fig 1. Serum concentrations of bone metabolism markers in relation to age and anthropometrics (n = 395). (a) tALP in relation to age. (b) OC in relation to
age. (c) β-CTx in relation to age. (d) tALP in relation to height. (e) OC in relation to height. (f) β-CTx in relation to height. (g) tALP in relation to weight. (h) OC in
relation to weight. (i) β-CTx in relation to weight. (j) tALP by BMI groups. (k) OC by BMI groups. (l) β-CTx by BMI groups. (m) tALP by trajectories of weight
gain. (n) OC by trajectories of weight gain. (o) β-CTx by trajectories of weight gain. Panels a) to i): the solid line represents the mean and the dotted lines ± 2SD; r,
Pearson correlation coefficient, rpartial, Pearson partial correlation coefficient (correlations between bone metabolism markers and age were controlled for sex and
season; between bone metabolism markers and height were controlled for sex, age and season; between bone metabolism markers and weight were controlled for
sex, age, height and season). For better data visualization, the participant with 95 months of age is not represented in Panels a) to c). Panels j) to l): p, p-values from
the Mann–Whitney test for comparisons between BMI groups; padjusted, p-values from the nlcom postestimation command for comparisons between BMI groups
(means of bone metabolism markers were adjusted for sex, age and season). Panel m) to o): p, p-values from ANOVA for comparisons between trajectories of
weight gain; padjusted, p-values from the testparm Stata command for comparisons between trajectories of weight gain (means of bone metabolism markers were
adjusted for sex, age, current body size and season). Abbreviations: tALP, total alkaline phosphatase; OC, osteocalcin; β-CTx, β-crosslaps; BMI, body mass index,
95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0219423.g001
Table 3. Pearson correlation and partial correlation coefficients between bone metabolism markers and bone mineral content and density, in girls and boys
(n = 395).
Subtotal BMC Lumbar spine BMC Subtotal aBMD Lumbar spine aBMD
Coefficient 95%CI Coefficient 95%CI Coefficient 95%CI Coefficient 95%CI
tALP Girls r = 0.25 0.12, 0.38 r = 0.18 0.05, 0.32 r = 0.24 0.11, 0.37 r = 0.19 0.06, 0.33
rpartial = 0.02 -0.12, 0.16 rpartial = 0.08 -0.06, 0.22 rpartial = 0.02 -0.12, 0.16 rpartial = 0.09 -0.05, 0.23
Boys r = 0.24 0.11, 0.37 r = 0.22 0.08, 0.35 r = 0.22 0.08, 0.35 r = 0.20 0.06, 0.33
rpartial = 0.11 -0.03, 0.25 rpartial = 0.13 -0.01, 0.27 rpartial = 0.10 -0.04, 0.23 rpartial = 0.13 -0.01, 0.26
OC Girls r = 0.23 0.09, 0.36 r = 0.14 0.00, 0.28 r = 0.20 0.06, 0.33 r = 0.26 0.12, 0.38
rpartial = 0.22 0.08, 0.35 rpartial = 0.10 -0.04, 0.23 rpartial = 0.20 0.06, 0.33 rpartial = 0.23 0.09, 0.36
Boys r = 0.19 0.05, 0.32 r = 0.06 -0.08, 0.20 r = 0.14 0.00, 0.28 r = 0.13 -0.01, 0.27
rpartial = 0.08 -0.06, 0.21 rpartial = -0.07 -0.21, 0.07 rpartial = 0.04 -0.10, 0.18 rpartial = 0.06 -0.08, 0.19
β-CTx Girls r = 0.07 -0.07, 0.21 r = 0.08 -0.06, 0.22 r = 0.01 -0.13, 0.15 r = 0.04 -0.10, 0.18
rpartial = 0.11 -0.03, 0.25 rpartial = 0.04 -0.10, 0.18 rpartial = 0.03 -0.11, 0.17 rpartial = 0.05 -0.09, 0.19
Boys r = 0.10 -0.04, 0.24 r = 0.07 -0.07, 0.21 r = 0.06 -0.08, 0.20 r = 0.09 -0.05, 0.22
rpartial = 0.04 -0.10, 0.18 rpartial = -0.02 -0.16, 0.12 rpartial = -0.00 -0.14, 0.14 rpartial = 0.06 -0.08, 0.19
Abreviations: tALP, total alkaline phosphatase; OC, osteocalcin; β-CTx, β-crosslaps; BMC, bone mineral content; aBMD, areal bone mineral density; r, Pearson
correlation coefficient; rpartial, Pearson partial correlation coefficient (age, body size and season controlled); 95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0219423.t003
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drawn in the morning, after an overnight fast. Nevertheless, our reported reference values are
directly applicable only to children of the same age whose samples were tested using laboratory
methods similar to ours [28], as supported by our comparison of the present results with previ-
ous descriptions (Tables A-C in S1 File). Regarding 25(OH)D, PTHi, Ca and Pi we found that
concentrations in our sample were within published reference intervals although no previous
studies have reported sex differences in serum concentration of Pi [35, 36]. However, our find-
ings on the relationships between bone metabolism markers and anthropometrics or DXA-
derived bone measures are more dependent on the relative positions of children in the distri-
bution of each marker and less on absolute value of marker concentrations, which makes for
safer generalization of the magnitude of associations to other contexts.
We found a positive correlation between OC and β-CTx, in agreement with findings in
other samples of prepubertal children [17] but in contrast with one study including 5 to 10
year-old children [14]. Positive relationships between bone-specific formation and resorption
markers are expected, and reflect the nature of bone turnover as a tightly regulated dynamic
mechanism of formation and resorption [6]. Our absence of correlation between tALP and
OC corroborates previous findings [37] but contradicts more recent results that showed direct
correlations among formation markers [13, 38]. The recent hypothesis that OC is a marker of
bone turnover as a whole, reflecting not only bone formation but also resorption, may explain
its less consistent associations with other formation markers [39]. Our results also differed
from previous findings that disclosed a positive relationship between ALP and β-CTx. How-
ever, other studies have assessed bone-specific ALP rather than total ALP [38]. In addition,
since previous studies have looked at wider age ranges, results are not straightforwardly com-
parable to ours in children of the same age.
Overall, weak correlations among bone markers are probably due to the coexistence of dif-
ferent biological processes at different anatomical regions and bone surfaces during skeletal
growth. In addition, markers are released during different stages of bone formation and
resorption, and have different elimination pathways and serum half-lives, which may affect
their relations at different time points during growth [6].
Our results were indicative of a weak positive effect of age on tALP concentrations, which
corroborates previous findings of an age-related increase in tALP, expected to peak at approxi-
mately 10–12 years of age in girls and 13–15 years in boys, and detectable around 7 years of
age [35, 36, 40–43]. At this age, tALP was slightly correlated with height. Also, higher concen-
trations were observed in overweight when compared to healthy weight participants, and in
children who gained weight above-average during infancy, in comparison to those in an aver-
age weight gain trajectory. These modest positive relationships between tALP and anthropo-
metric growth, which were not apparent for the bone-specific markers OC and β-CTx, suggest
that tALP is a more specific marker of the child’s overall growth trajectory up to the time of
measurement. Positive correlations between bone-specific ALP and anthropometric measures
have been reported elsewhere [38] while others shown no effect of BMI on tALP values [44].
Our results did not support previously described positive correlations between OC and height
and weight [10, 14], between CTX and weight [14] and height [13, 38] or the finding of
decreased OC values in obese when compared to healthy weight children [11, 12]. However, in
accordance to our findings, a number of other studies have contributed with evidence of a lack
of association between height, weight or BMI and OC [9, 10, 13, 14, 39, 44] and height or BMI
and β-CTx [44]. Increased formation markers in taller and heavier children are likely reflecting
greater growth velocity, inducing increased bone formation in response to greater mechanical
strain [13, 32]. Accordingly, CTX may also correlate with height since increased periosteal
modeling also implies removal of bone at the endocortical surface [45]. To the best of our
knowledge, our study is the first to estimate relationships between bone markers and growth
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trajectories from birth. Given the lack of relationships between OC or β-CTx and trajectories
of weight gain we believe that, contrarily to dimensions of skeletal growth, such as BMC, that
are clearly shaped by the overall weight trajectory, markers of bone metabolism are not related
to overall weight trajectories [46]. The lack of associations between OC or β-CTx and the
remaining anthropometric growth indices supports this assertion.
Bone metabolism markers were also only weakly correlated with DXA-derived BMC and
aBMD. Additional adjustments for age, body size and season attenuated those relationships
only for OC and only in girls. This suggests that measurements of bone metabolism markers at
a single point in time do not reflect bone mineralization status in the general prepubertal pop-
ulation and are unlikely to be helpful for monitoring the status of bone mineral accrual in
non-clinical settings. These findings are consistent with the premise that bone markers reflect
instantaneous metabolic activity and do not directly translate physical dimensions that result
from the cumulative process of bone gain throughout several years [6]. In prepubertal chil-
dren, some previous studies have also found no relationship between tALP, OC or β-CTx and
whole body (WB) and LS BMC or BMD [14, 15, 35]. Other studies disclosed, however, consis-
tent positive relationships between tALP and OC and WB and LS BMC, in boys [16] and
between OC and CTX and WB and LS BMC/BMD, in both sexes [15, 17]. In older pubertal
children, inverse correlations between serum OC or CTX and BMD were disclosed [9, 15],
which is expected because, during puberty, bone turnover decreases with advancing sexual
maturation while, at the same time, bone mass accrual continues up to peak bone mass [7].
Some authors have also described site-specific associations between bone metabolism markers
and bone mass during puberty, disclosing stronger relationships in anatomical sites with more
trabecular bone (e.g. LS BMC) than with cortical bone (FN BMC), possibly due to higher met-
abolic activity of trabecular when compared to cortical bone [47]. In our study, however, bone
markers were not correlated with either cortical or trabecular bone when we computed corre-
lations between bone markers and BMC and aBMD at the LS and lower limbs (Table D in S1
File).
This study extends previous evidence by assessing the usefulness of bone markers to
describe growth in a population-based sample of children with longitudinal anthropometric
data. In particular, we were able to investigate for the first time the relationships of bone mark-
ers with weight gain trajectories since birth. We also quantified bone metabolism markers at
the same chronological age for all participants. Furthermore, blood samples were all collected
in the morning after overnight fasting to avoid the variability associated to the circadian
rhythm. In addition, reference intervals were described according the statistical approach rec-
ommended in the C28-A3 CLSI/IFCC guidelines [28]. However, we should acknowledge a
limitation in our use of tALP instead of bone-specific ALP. Serum variations of tALP are not
as accurate as bone-specific ALP to detect subtle changes in bone formation [6]. Nevertheless,
when liver ALP is stable and remains within normal values, tALP represents a valid marker of
bone turnover [31].
In the future, it will be interesting to investigate time changes in bone markers and whether
those are associated with changes in bone mass and density across the lifespan. In particular, it
might be important to explore how puberty relates to bone formation and resorption.
Although we were not able to assess sexual development in this evaluation, we expect that the
vast majority of children from the general population were prepubertal at 7 years of age, as
observed in previous population-based samples of the same age [48, 49].
In conclusion, we found weak or negligible associations of bone metabolism markers with
different indices of growth, suggesting limited ability of those markers to predict bone status
and overall growth in 7-year-old children from the general population.
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